Covance Laboratories, Inc, Bioanalytical Chemistry, 3301 Kinsman Boulevard, Madison, Wisconsin 53704, USA.
J Mass Spectrom. 2012 May;47(5):655-67. doi: 10.1002/jms.3015.
Dried blood spot (DBS) sampling has gained considerable interest as a microsampling technique to support drug discovery and development owing to its enormous ethical and practical benefits. Quantitative determinations of drugs and/or their metabolites collected in DBS matrix in its current format, however, have encountered technical challenges and regulatory uncertainty. The challenges of DBS bioanalysis are largely ascribed to the way how samples are collected and analyzed. Currently, an uncontrolled amount of a blood sample, e.g. 20 µl, is collected per time point per sample and spotted onto cellulose paper. Quantitation is based on removal of a fixed area of the DBS sample, resulting in sample waste, a need for mechanical punching and concomitant potential punching carryover, uncertainty in recovery assessment and the adverse impact of hematocrit on accurate quantitation. Here, we describe the concept and applications of a novel concept, namely perforated dried blood spot (PDBS), for accurate microsampling that addresses previous challenges. Advantages of PDBS are enumerated and compared with conventional DBS in the context of microsampling and liquid chromatography tandem mass spectrometry bioanalysis. Two approaches for accurate microsampling of a small volume of blood (5 µl) are proposed and demonstrated, i.e. Microsafe® pipettes and the Drummond incremental pipette. Two online sample enrichment techniques to enhance liquid chromatography tandem mass spectrometry sensitivity for microsampling bioanalysis are discussed. The PDBS concept was successfully applied for accurate sample collection (5 µl) in a toxicokinetic study in rats given a single oral gavage dose of acetaminophen. Perspectives on bioanalytical method validation for regulated DBS/PDBS microsampling are also presented.
干血斑 (DBS) 采样作为一种微量采样技术,因其具有巨大的伦理和实际效益,在药物发现和开发中引起了广泛关注。然而,以其当前形式收集的 DBS 基质中的药物和/或其代谢物的定量测定遇到了技术挑战和监管不确定性。DBS 生物分析的挑战主要归因于样品的采集和分析方式。目前,每次采集每个样本时,会采集不定量的血液样本(例如 20 µl)并点到纤维素纸上。定量是基于去除 DBS 样品的固定面积,导致样品浪费、需要机械打孔以及随之而来的潜在打孔转移、回收率评估的不确定性以及红细胞压积对准确定量的不利影响。在这里,我们描述了一种新颖概念的概念和应用,即穿孔干血斑 (PDBS),用于解决先前挑战的准确微量采样。在微量采样和液相色谱串联质谱生物分析的背景下,枚举了 PDBS 的优点并将其与常规 DBS 进行了比较。提出并演示了两种用于准确采集小体积血液(5 µl)的微量采样方法,即 Microsafe®移液器和 Drummond 增量移液器。讨论了两种用于增强微采样生物分析液相色谱串联质谱灵敏度的在线样品富集技术。PDBS 概念成功应用于大鼠单次口服灌胃给予扑热息痛后的毒代动力学研究中准确的样品采集(5 µl)。还介绍了用于受监管的 DBS/PDBS 微量采样的生物分析方法验证的观点。